SecBot SecBot
8-K ·Filed Feb 26, 2026

RYTM

RHYTHM PHARMACEUTICALS, INC.
BULLISH
Impact 8/10
Horizonweeks Processed8mo ago SEC0001628280-26-011987
8-K Item 2.02: Earnings release
Actionable Insight ▲ Bullish

The combination of strong revenue growth, improving financial position, and multiple near-term catalysts (PDUFA decision, topline data readouts) creates a favorable risk-reward profile. Traders should monitor the March 20 FDA decision on setmelanotide for acquired HO as a potential significant upside catalyst.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$98.07
T+0 close · Feb 26, 2026 · via day close
Latest settled
−8.04%
T+60 · $90.19
Vs SPY
−15.79%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Feb 26 $98.07entry
  2. T+1 · 9mo ago −5.45%α −4.99% · $92.73
  3. T+5 · 9mo ago −6.74%α −5.61% · $91.46
  4. T+20 · 8mo ago −16.49%α −10.09% · $81.90
  5. T+60 · 6mo ago −8.04%α −15.79% · $90.19
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Rhythm Pharmaceuticals reported strong fourth quarter and full year 2025 financial results, with Q4 net product revenue of $57.3 million, representing 12% sequential growth and 37% year-over-year growth. The company also highlighted key clinical progress, including a positive end-of-Phase-2 meeting with the FDA for bivamelagon and upcoming PDUFA decision for setmelanotide in acquired hypothalamic obesity on March 20, 2026. Cash position increased to $388.9 million, providing funding for at least 24 months.

Key Financial Metrics

Revenue
$194.8M
+49.7% YoY
EPS
$-0.73

Key Facts

  • Q4 2025 net product revenue was $57.3 million, up 12% sequentially and 37% year-over-year from $41.8 million in Q4 2024
  • Full year 2025 revenue was $194.8 million, up 50% from $130.1 million in 2024
  • Net loss attributable to common stockholders was $48.8 million in Q4 2025, improved from $44.6 million in Q4 2024
  • Cash, cash equivalents and short-term investments were $388.9 million as of December 31, 2025, up from $320.6 million as of December 31, 2024
  • FDA PDUFA goal date for sNDA for setmelanotide in acquired hypothalamic obesity is March 20, 2026
  • Company expects to initiate Phase 3 trial for bivamelagon in acquired HO by year-end 2026

Financial Impact

Revenue grew 37% year-over-year in Q4 and 50% for the full year, while cash position increased by $68.3 million year-over-year

revenuecashnet loss

Segment Breakdown

SegmentRevenueGrowth
IMCIVREE$194.8M+49.7%

Risk Factors

  • FDA may not approve setmelanotide for acquired hypothalamic obesity indication
  • Upcoming clinical trial data readouts in March 2026 could be disappointing
  • Operating expenses are expected to increase significantly in 2026 ($385M-$415M non-GAAP)

Market Snapshot

Exchange
Nasdaq

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001628280-26-011987
Document: 0001628280-26-011987-index.html0001628280-26-011987
Document: 0001628280-26-011987.txt0001628280-26-011987

Track record

26 reports on RYTM

Performance horizon

9 of 13 bullish or bearish reports moved the stock their way by T+5. Best: +32.06% at T+60 after the May 1, 2026 report. 11 of 13 went positive at some point.

Filters
  1. Nov 16, 2026today Press Release Bullish 5/10 Entry $107.48 Now $107.48 +0.00% settles Nov 24
  2. Nov 4, 202612d ago Institutional Cluster Neutral 3/10 Entry $110.68 to $112.16 Now $107.48 −2.89% ▲ +1.34% +2.25% vs SPY
  3. Nov 4, 202612d ago Press Release Bullish 5/10 Entry $110.68 to $112.16 Now $107.48 −2.89% ▲ +1.34% +2.25% vs SPY
  4. Nov 3, 202613d ago 8-K Bullish 6/10 No price data
  5. Nov 3, 202613d ago Press Release Bullish 6/10 Entry $86.44 to $113.95 Now $107.48 +24.34% ▲ +31.83% +32.41% vs SPY
  6. Nov 2, 202614d ago Press Release Neutral 5/10 Entry $86.44 to $113.95 Now $107.48 +24.34% ▲ +31.83% +32.41% vs SPY
  7. Oct 13, 20264w ago Press Release Bullish 6/10 Entry $86.71 to $88.62 Now $107.48 +23.95% ▲ +2.20% +1.75% vs SPY
  8. Oct 13, 20264w ago SC 13G Neutral 3/10 Entry $86.61 to $90.20 Now $107.48 +24.10% ▲ +4.14% +5.30% vs SPY
  9. Sep 14, 20269w ago 144 Bearish 5/10 Entry $96.77 to $99.27 Now $107.48 −11.07% ▼ −2.58% −0.47% vs SPY
  10. Aug 17, 202613w ago Insider Cluster Bearish 6/10 Entry $115.25 to $113.35 Now $107.48 +6.74% ▲ +1.65% +1.45% vs SPY
Showing 10 of 26

US Market Status

Market Closed · Opens in 8h 57m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Feb 26, 2026